Stimulation of glucose uptake inmurine soleusmuscle and adipocytes by 5-(4-phenoxybutoxy)psoralen (PAP-1) may be mediated by Kv1.5 rather than Kv1.3

PeerJ

Volumn 2014, Issue 1, 2014, Pages

  Ngala, Robert A ^a,b   Zaibi, Mohamed S ^a   Langlands, Kenneth ^a   Stocker, Claire J ^a   Arch, Jonathan R S ^a   Cawthorne, Michael A ^a  

^a UNIVERSITY OF BUCKINGHAM   (United Kingdom)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

Adipocyte; Glucose uptake; Kv1.3; Kv1.5; PAP 1; Potassium channel; Soleus muscle; TNFa

Indexed keywords

MUS;

EID: 84949120568     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.614     Document Type: Article

References (25)

1. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, Andrews BS, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, NepomGT, Gutman GA, Calabresi PA, Chandy KG. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 103:17414-17419 DOI 10.1073/pnas.0605136103.
2. Calle MC, Fernandez ML. 2012. Inflammation and type 2 diabetes. Diabetes & Metabolism 38:183-191 DOI 10.1016/j.diabet.2011.11.006.
3. Choi BH, Hahn SJ. 2010. Kv1.3: a potential pharmacological target for diabetes. ACTA Pharmacologica Sinica 31:1031-1035 DOI 10.1038/aps.2010.133.
4. Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath Z, Matschke K, Varro A, Ravens U. 2013. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. Journal of Cardiovascular Pharmacology 61:408-415 DOI 10.1097/FJC.0b013e31828780eb.
5. Galvez BG, SanMartin N, Rodriguez C. 2009. TNF-alpha is required for the attraction of mesenchymal precursors to white adipose tissue in ob/ob mice. PLoS ONE 4:e4444 DOI 10.1371/journal.pone.0004444.
6. Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP, Schmalhofer W, Kaczorowski GJ, Garcia ML. 1993. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. Journal of Biological Chemistry 268:18866-18874.
7. Grande M, Suarez E, Vicente R, Canto C, Coma M, Tamkun MM, Zorzano A, Guma A, Felipe A. 2003. Voltage-dependent K+ channel beta subunits in muscle: differential regulation during postnatal development and myogenesis. Journal of Cellular Physiology 195:187-193 DOI 10.1002/jcp.10203.
8. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG. 1994. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Molecular Pharmacology 45:1227-1234.
9. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS. 2003. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacological Reviews 55:583-586 DOI 10.1124/pr.55.4.9.
10. Irwin PL, Nguyen LH, Chen CY, Uhlich GA, Paoli GC. 2012. A method for correcting standard-based real-time PCR DNA quantitation when the standard's polymerase reaction efficiency is significantly different from that of the unknown's. Analytical and Bioanalytical Chemistry 402:2713-2725 DOI 10.1007/s00216-012-5737-9.
11. Kang LS, Kim S, Dominguez 2nd JM, Sindler AL, Dick GM, Muller-Delp JM. 2009. Aging and muscle fiber type alter K+ channel contributions to the myogenic response in skeletal muscle arterioles. Journal of Applied Physiology (1985) 107:389-398 DOI 10.1152/japplphysiol.91245.2008.
12. Kashiwagi A, Huecksteadt TP, Foley JE. 1983. The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. Journal of Biological Chemistry 258:13685-13692.
13. Li Y, Wang P, Xu J, Desir GV. 2006. Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. American Journal of Physiological Cell Physiology 290:C345-C351 DOI 10.1152/ajpcell.00091.2005.
14. Ngala RA, O'Dowd J, Wang SJ, Agarwal A, Stocker C, Cawthorne MA, Arch JR. 2008. Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and ß2-adrenoceptor mechanisms. British Journal of Pharmacology 155:395-406 DOI 10.1038/bjp.2008.244.
15. Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. 2012. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. Circulation: Arrhythmia and Electrophysiology 5:1193-1201 DOI 10.1161/CIRCEP.111.969782.
16. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. 2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Molecular Pharmacology 68:1254-1270 DOI 10.1124/mol.105.015669.
17. Straub SV, Perez SM, Tan B, Coughlan KA, Trebino CE, Cosgrove P, Buxton JM, Kreeger JM, Jackson VM. 2011. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. American Journal of Physiology, Endocrinology and Metabolism 301:E380-E390 DOI 10.1152/ajpendo.00076.2011.
18. Tschritter O, Machicao F, Stefan N, Schafer S, Weigert C, Staiger H, Spieth C, Haring HU, Fritsche A. 2006. A new variant in the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism 91:654-658 DOI 10.1210/jc.2005-0725.
19. Tucker K, Overton JM, Fadool DA. 2008. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. International Journal of Obesity 32:1222-1232 DOI 10.1038/ijo.2008.77.
20. Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG. 2013. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 110:E2239-E2248 DOI 10.1073/pnas.1221206110.
21. Wargent ET, O'Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ. 2013. Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. Journal of Endocrinology 216:157-168 DOI 10.1530/JOE-12-0402.
22. Xu J, Koni PA, Wang P, Li G, Kaczmarek L, Wu Y, Li Y, Flavell RA, Desir GV. 2003. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Human Molecular Genetics 12:551-559 DOI 10.1093/hmg/ddg049.
23. Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV. 2004. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America 101:3112-3117 DOI 10.1073/pnas.0308450100.
24. You MH, Song MS, Lee SK, Ryu PD, Lee SY, Kim DY. 2013. Voltage-gated K+ channels in adipogenic differentiation of bone marrow-derived human mesenchymal stem cells. ACTA Pharmacologica Sinica 34:129-136 DOI 10.1038/aps.2012.142.
25. Zaibi MS, Stocker CJ, O'Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR. 2010. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Letters 584:2381-2386 DOI 10.1016/j.febslet.2010.04.027.